Patisiran
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Patisiran: From hATTR Amyloidosis with Polyneuropathy to Dermatitis
One-Sentence Summary
Patisiran (DrugBank DB14582) is an siRNA therapeutic approved for hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, silencing TTR mRNA production in the liver. The TxGNN model predicts it may be effective for Dermatitis, but this prediction is currently supported by no clinical trials and no published literature — it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | hATTR amyloidosis with polyneuropathy |
| Predicted New Indication | Dermatitis |
| TxGNN Prediction Score | 90.65% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on known information, patisiran is a small interfering RNA (siRNA) therapeutic delivered via lipid nanoparticle that silences transthyretin (TTR) mRNA production in hepatocytes, reducing circulating TTR protein and its pathological deposition. Its efficacy in hATTR amyloidosis with polyneuropathy is established.
Dermatitis is a heterogeneous inflammatory skin condition with no known relationship to TTR amyloid deposition or hepatic gene silencing pathways. The evidence pack’s own mechanistic rationale is explicit on this point: it states the prediction likely reflects the topological proximity of disease nodes within the knowledge graph rather than an identifiable shared biological mechanism.
Given the absence of a defined mechanistic pathway and the complete lack of clinical or literature evidence, this prediction should be treated as a hypothesis-generating signal only, not as a basis for clinical consideration at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Note: TFDA-equivalent warning and contraindication data for patisiran is currently unavailable in this evidence pack (flagged as a Blocking data gap), which prevents a formal safety pre-assessment (S1) for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or literature evidence supporting patisiran’s use in dermatitis, and the mechanistic rationale itself notes no established biological link — the prediction likely reflects knowledge-graph topology rather than pharmacology. A separate Blocking data gap (missing TFDA/PI safety data) also prevents safety pre-assessment regardless of efficacy evidence.
To proceed, the following is needed:
- TFDA-equivalent product information (warnings, contraindications) to unblock safety pre-assessment
- Detailed mechanism of action data from DrugBank or primary literature
- Preclinical or mechanistic studies establishing a biological rationale connecting TTR silencing to dermatitis
- Any emerging clinical trial or case-report evidence in this indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.